GeoVax Labs (GOVX) Cash from Investing Activities (2013 - 2025)
GeoVax Labs (GOVX) posted quarterly Cash from Investing Activities of -$10718.0 for Q2 2025, up 36.56% quarter-over-quarter from -$16894.0 in Q1 2025.
GeoVax Labs (GOVX) Cash from Investing Activities (2013 - 2025) Analysis & Trends
GeoVax Labs (GOVX) has reported Cash from Investing Activities for 11 consecutive years, with -$10718.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Cash from Investing Activities changed N/A year-over-year to -$10718.0; the TTM figure through Dec 2025 stood at -$27612.0 (down 33.69% YoY), while the FY2025 annual figure was -$27612.0, down 33.69% from the prior year.
- Cash from Investing Activities rose to -$10718.0 in Q2 2025 per GOVX's latest filing, from -$16894.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$6192.0 in Q3 2023 and bottomed at -$62186.0 in Q1 2022.
- Historically, Cash from Investing Activities has averaged -$25380.6 across 5 years, with a median of -$20197.0 in 2022.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities plunged 1025.06% — and 2023, when it soared 88.06%.
- GeoVax Labs' Cash from Investing Activities stood at -$27789.0 in 2021, then plunged by 86.67% to -$51875.0 in 2022, then soared by 63.47% to -$18949.0 in 2023, then retreated by 8.99% to -$20653.0 in 2024, then soared by 48.1% to -$10718.0 in 2025.
- Business Quant data shows GOVX's Cash from Investing Activities at -$10718.0 in Q2 2025, -$16894.0 in Q1 2025, and -$20653.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -10,718.00 |
| Jun 30, 2025 | -10,718.00 |
| Mar 31, 2025 | -16,894.00 |
| Mar 31, 2025 | -16,894.00 |
| Sep 30, 2024 | -20,653.00 |
| Sep 30, 2024 | -20,653.00 |
| Dec 31, 2023 | -18,949.00 |
| Dec 31, 2023 | -18,949.00 |
| Sep 30, 2023 | -6,192.00 |
| Sep 30, 2023 | -6,192.00 |
| Jun 30, 2023 | -23,805.00 |
| Jun 30, 2023 | -23,805.00 |
| Sep 30, 2022 | -51,875.00 |
| Sep 30, 2022 | -51,875.00 |
| Jun 30, 2022 | -20,197.00 |
| Jun 30, 2022 | -20,197.00 |
| Mar 31, 2022 | -62,186.00 |
| Mar 31, 2022 | -62,186.00 |
| Sep 30, 2021 | -27,789.00 |
| Sep 30, 2021 | -27,789.00 |